Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00489372 · ClinicalTrials.gov registry record · Phase 1
Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients
A Phase 1 study of Healthy, no Evidence of Disease, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT00489372: Completed Phase 1 study of Healthy, no Evidence of Disease, sponsored by National Cancer Institute (NCI).
NCT00489372 is a Phase 1 study of Healthy, no Evidence of Disease that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 174-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00489372, a Phase 1 study of Healthy, no Evidence of Disease, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.
Primary Outcome
Summarized using descriptive statistics.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- OTHER pharmacological study
- DRUG Se-methyl-seleno-L-cysteine
Study Locations (2)
Illinois
- Northwestern University - Chicago
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00489372 record still lists
NCT00489372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 174-participant average among 11 other Healthy, no Evidence of Disease trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Healthy, no Evidence of Disease appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00489372 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00489372 about?
NCT00489372 is a clinical study titled "Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients". This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-meth...
What is the current status of trial NCT00489372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2009-07.
What conditions does trial NCT00489372 study?
This clinical trial studies the following conditions: Healthy, no Evidence of Disease.
What interventions are being tested in trial NCT00489372?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), pharmacological study (OTHER), Se-methyl-seleno-L-cysteine (DRUG).
Who is sponsoring clinical trial NCT00489372?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00489372 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy, no Evidence of Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00489372's enrollment target sits among peer trials
36 6th of 11 higher than 6 of 11 other Healthy, no Evidence of Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy, no Evidence of Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studying Different Formulations of SR13668 in Healthy Volunteers
COMPLETED · Phase 1
-
Diindolylmethane in Healthy Volunteers
COMPLETED · Phase 1
-
Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers
COMPLETED · Phase 1
-
Lycopene in Healthy Male Participants
COMPLETED · Phase 1
-
Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer
COMPLETED · Phase 1
-
A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia